ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., $(MXCT)$, a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its third quarter ended September 30, 2025 financial results and reiterated its 2025 guidance.
Third Quarter and Recent Highlights
-- Core business revenue of $6.4 million in the third quarter of 2025.
-- Strategic Platform License SPL Program-related revenue was $0.4 million
for the third quarter of 2025.
-- Total revenue of $6.8 million in the third quarter of 2025.
-- MaxCyte added one new SPL client, Moonlight Bio, in October, in addition
to Adicet Bio and Anocca AB in July. The total number of SPL agreements
stands at 32.
-- Total cash, cash equivalents and investments were $158.0 million as of
September 30, 2025.
"We remain on track to achieve our full year 2025 revenue guidance," said Maher Masoud, President and CEO of MaxCyte. "In the third quarter, we announced an operational restructuring to significantly reduce costs and accelerate our path towards profitability, while strengthening our ability to grow over the long-term. Though the external cell and gene therapy operating environment has rationalized over the last few years, we firmly believe that our value proposition for customers remains strong, as evidenced by recently signing our fourth SPL this year, Moonlight Bio. We remain committed to continued investments in SeQure Dx, product enhancement initiatives, and expanding the breadth of our cell engineering offerings, but will do so with commercial discipline to produce long-term sustainable growth for MaxCyte."
The following tables provide details regarding the sources of the Company's revenue for the periods presented.
Three Months Ended
September 30
(Unaudited)
---------------------- ----------
2025 2024 % Change
------------ -------- ----------
(in thousands, except
percentages)
Instruments $ 1,376 $ 1,764 (22%)
PAs and consumables 2,577 3,432 (25%)
Licenses 1,803 2,528 (29%)
Assay services 248 -- --
Other 402 416 (3%)
-------- -------
Total Core Revenue $ 6,406 $ 8,140 (21%)
-------- -------
Program-Related 423 24 1,663%
-------- -------
Total Revenue $ 6,829 $ 8,164 (16%)
======== =======
In addition to revenue, management regularly reviews key business metrics to evaluate our business, measure performance, identify trends affecting our business, formulate financial projections and make strategic decisions. As of the dates presented, these key metrics were as follows:
Three Months Ended September 30,
--------------------------------------
2025 2024
------------------- -----------------
Installed base of instruments (sold or
leased) 830 739
Core Revenue Generated by SPL Clients
as a % of Core Revenue 53% 53%
Third Quarter 2025 Financial Results
Total revenue for the third quarter of 2025 was $6.8 million, compared to $8.2 million in the third quarter of 2024, representing a decrease of 16%.
Core business revenue (sales of instruments, PAs and consumables, assay services, and licenses to customers, excluding SPL Program-related revenue) for the third quarter of 2025 was $6.4 million, compared to $8.1 million in the third quarter of 2024, representing a decrease of 21%.
SPL Program-related revenue was $0.4 million in the third quarter of 2025, as compared to immaterial in the third quarter of 2024.
Gross profit for the third quarter of 2025 was $5.2 million (77% gross margin), compared to $6.2 million (76% gross margin) in the third quarter of 2024. Non-GAAP adjusted gross margin was 81% excluding SPL Program-related revenue and reserves for excess and obsolete inventory, compared to non-GAAP adjusted gross margin of 85% in the third quarter of 2024.
Operating expenses for the third quarter of 2025 were $19.4 million, compared to operating expenses of $20.3 million in the third quarter of 2024.
Third quarter 2025 net loss was $12.4 million compared to net loss of $11.6 million for the same period in 2024. Adjusted EBITDA, a non-GAAP measure, was a loss of $10.0 million for the third quarter of 2025, compared to a loss of $13.0 million for the third quarter of 2024; stock-based compensation expense was $2.0 million in the third quarter of 2025 compared to $3.4 million in the third quarter of 2024.
2025 Guidance
MaxCyte reiterates 2025 revenue guidance for core business revenue and SPL Program-related revenue:
-- Core revenue is expected to be flat to a 10% decline compared to 2024,
inclusive of revenue from SeQure Dx.
-- SPL Program-related revenue is expected to be approximately $5 million
for the year. SPL-program related revenue guidance includes both expected
revenue from pre-commercial milestone payments and commercial
royalties/sales-based payments.
MaxCyte expects to end 2025 with $152 million to $155 million in total cash, cash equivalents and investments. Our revised guidance reflects near term cash utilization from the operational restructuring announced on September 22, 2025.
Webcast and Conference Call Details
MaxCyte will host a conference call today, November 12, 2025, at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the "Events" section of the MaxCyte website at https://investors.maxcyte.com/.
About MaxCyte
At MaxCyte$(R)$, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation(R) technology and SeQure DX$(TM)$ gene editing risk assessment services enable precise, efficient and scalable cell engineering. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine. Learn more at maxcyte.com and follow us on X and LinkedIn.
Non-GAAP Financial Measures
This press release contains EBITDA, which is a non-GAAP measure defined as earnings before interest income and expense, taxes, depreciation and amortization. This press release also contains Adjusted EBITDA, which is a non-GAAP measure defined as earnings before interest, taxes, depreciation, amortization and one-time restructuring charges. MaxCyte believes that EBITDA and Adjusted EBITDA provide useful information to management and investors relating to its results of operations. The company's management uses these non-GAAP measures to compare the company's performance to that of prior periods for trend analyses, and for budgeting and planning purposes. The company believes that the use of EBITDA and Adjusted EBITDA provide an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing the company's financial measures with other companies, many of which present similar non-GAAP financial measures to investors, and that it allows for greater transparency with respect to key metrics used by management in its financial and operational decision-making.
This press release also contains Non-GAAP Gross Margin, which we define as Gross Margin when excluding SPL program related revenue and reserves for excess and obsolete inventory. The Company believes that the use of Non-GAAP Gross Margin provides an additional tool to investors because it provides consistency and comparability with past financial performance, as Non-GAAP Gross Margin excludes non-core revenues and inventory reserves, which can vary significantly between periods and thus affect comparability.
Management does not consider these Non-GAAP financial measures in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of these Non-GAAP financial measures is that they exclude significant revenues and expenses that are required by GAAP to be recorded in the Company's financial statements. In order to compensate for these limitations, management presents these Non-GAAP financial measures along with GAAP results. Non-GAAP measures should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. Reconciliation tables of net loss, the most comparable GAAP financial measure, to EBITDA and Adjusted EBITDA, and Gross Margin, the most comparable GAAP financial measure, to Non-GAAP Gross Margin, are included at the end of this release. MaxCyte urges investors to review the reconciliation and not to rely on any single financial measure to evaluate the company's business
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements about us and our industry involve substantial known and unknown risks, uncertainties, and assumptions, including those described in Item 1A under the heading "Risk Factors" and elsewhere in our report on Form 10-K, that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements include, but are not limited to, statements about the Company's preliminary results of operations, including fourth quarter and full year total revenue, core revenue, and SPL program revenue and statements about possible or future results of operations or financial position. In some cases, you can identify forward-looking statements because they contain words such as "may," "might," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "seek," "predict," "future," "project," "potential," "continue," "contemplate," "target," the negative of these words and similar words or expressions. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements. The forward-looking statements contained in this press release, include, without limitation, statements concerning the following: our expected future growth and success of our business model; the size and growth potential of the markets for our products, and our ability to serve those markets, increase our market share, and achieve and maintain industry leadership; our ability to expand our customer base and enter into additional SPL partnerships; our financial performance and capital requirements; the adequacy of our cash resources and availability of financing on commercially reasonable terms; our expectations regarding general market and economic conditions that may impact investor confidence in the biopharmaceutical industry and affect the amount of capital such investors provide to our current and potential partners; and our use of available capital resources.
These and other risks and uncertainties are described in greater detail in Item 1A , entitled "Risk Factors," in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on March 11, 2025, as well as in discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time. These documents are available through the Investor Menu, Financials section, under "SEC Filings" on the Investors page of our website at http://investors.maxcyte.com. Any forward-looking statements in this press release are based on our current beliefs and opinions on the relevant subject based on information available to us as of the date of such press release, and you should not rely on forward-looking statements as predictions of future events. We undertake no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
MaxCyte Contacts:
Investor Relations
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com
Media Contact
Oak Street Communications
Kristen White
kristen@oakstreetcommunications.com
415.608.6060
MaxCyte, Inc.
Unaudited Consolidated Balance Sheets
(in thousands, except share and per share amounts)
September 30, 2025 December 31, 2024
-------------------- ---------------------
Assets
Current assets:
Cash and cash equivalents $ 12,973 $ 27,884
Short-term investments, at
amortized cost 92,755 126,598
Accounts receivable, net 8,306 4,682
Inventory 7,611 8,914
Prepaid expenses and other
current assets 3,000 3,606
--------------- --------------
Total current assets 124,645 171,684
Investments, non-current, at
amortized cost 52,274 35,781
Property and equipment, net 18,620 19,707
Right-of-use asset -
operating leases 11,135 10,766
Goodwill 3,554 --
Intangible assets, net 667 --
Other assets 2,581 1,532
Total assets $ 213,476 $ 239,470
=============== ==============
Liabilities and stockholders'
equity
Current liabilities:
Accounts payable $ 1,286 $ 1,358
Accrued expenses and other 8,306 8,302
Operating lease liability,
current 1,314 864
Deferred revenue, current
portion 5,196 5,251
--------------- --------------
Total current liabilities 16,102 15,775
Operating lease liability,
net of current portion 16,847 17,170
Contingent consideration 25 --
Other liabilities 227 274
--------------- --------------
Total liabilities 33,201 33,219
Commitments and contingencies
Stockholders' equity
Preferred stock, $0.01 par
value; 5,000,000 shares
authorized and no shares
issued and outstanding at
September 30, 2025 and
December 31, 2024 -- --
Common stock, $0.01 par
value; 400,000,000 shares
authorized, 106,644,343 and
105,711,093 shares issued
and outstanding at September
30, 2025 and December 31,
2024, respectively 1,066 1,057
Additional paid-in capital 431,096 422,047
Accumulated deficit (251,887) (216,853)
--------------- --------------
Total stockholders' equity 180,275 206,251
--------------- --------------
Total liabilities and
stockholders' equity $ 213,476 $ 239,470
=============== ==============
MaxCyte, Inc.
Unaudited Consolidated Statements of Operations
(in thousands, except share and per share amounts)
Three Months Ended September Nine Months Ended September
30, 30,
---------------------------- ------------------------------
2025 2024 2025 2024
------------- ------------- ------------- ---------------
Revenue $ 6,829 $ 8,164 $ 25,726 $ 29,934
Cost of goods
sold 1,596 1,928 4,612 4,819
----------- ----------- ----------- -----------
Gross profit 5,233 6,236 21,114 25,115
----------- ----------- ----------- -----------
Operating
expenses:
Research and
development 5,316 5,316 17,488 17,613
Sales and
marketing 3,936 6,207 15,420 20,188
General and
administrative 6,028 7,745 22,634 22,487
Restructuring
expense 3,058 - 3,058 -
Depreciation
and
amortization 1,044 1,021 3,185 3,123
----------- ----------- ----------- -----------
Total operating
expenses 19,382 20,289 61,785 63,411
----------- ----------- ----------- -----------
Operating loss (14,149) (14,053) (40,671) (38,296)
----------- ----------- ----------- -----------
Other income:
Interest income 1,733 2,496 5,637 7,838
----------- ----------- ----------- -----------
Total other
income 1,733 2,496 5,637 7,838
----------- ----------- ----------- -----------
Net loss $ (12,416) $ (11,557) $ (35,034) $ (30,458)
=========== =========== =========== ===========
Basic and
diluted net
loss per
share $ (0.12) $ (0.11) $ (0.33) $ (0.29)
=========== =========== =========== ===========
Weighted
average shares
outstanding,
basic and
diluted 106,613,075 105,109,603 106,324,792 104,614,679
=========== =========== =========== ===========
MaxCyte, Inc.
Unaudited Consolidated Statements of Cash Flows
(in thousands)
Nine Months ended September 30,
2025 2024
------------------------ --------------------------
Cash flows from
operating
activities:
Net loss $ (35,034) $ (30,458)
Adjustments to
reconcile net loss
to net cash used
in operating
activities:
Depreciation and
amortization 3,268 3,258
Lease
right-of-use
asset
amortization 587 353
Net book value
of consigned
equipment sold 70 35
Loss on disposal
of property and
equipment 132 462
Stock-based
compensation 8,507 9,949
Credit loss
expense
(recovery) 29 (130)
Change in
excess/obsolete
inventory
reserve 525 834
Amortization of
discounts on
investments (2,219) (5,052)
Changes in
operating assets
and liabilities,
net of effects of
acquisition:
Accounts
receivable (3,649) 1,348
Inventory 647 835
Prepaid expense
and other
current assets 744 (225)
Other assets (924) (732)
Accounts
payable,
accrued
expenses and
other (3,338) (1,420)
Operating lease
liability (939) (424)
Deferred revenue (80) 1,584
Other
liabilities (47) (6)
---------------------- ----------------------
Net cash used in
operating
activities (31,721) (19,789)
---------------------- ----------------------
Cash flows from
investing
activities:
Purchases of
investments (98,031) (118,339)
Maturities of
investments 117,600 128,440
Purchases of
property and
equipment (1,537) (1,504)
Acquisition of
business, net of
cash acquired of
$541 (1,773) --
---------------------- ----------------------
Net cash provided
by investing
activities 16,259 8,597
---------------------- ----------------------
Cash flows from
financing
activities:
Proceeds from
exercise of stock
options 417 1,379
Proceeds from
issuance of
common stock
under employee
stock purchase
plan 134 265
---------------------- ----------------------
Net cash provided
by financing
activities 551 1,644
---------------------- ----------------------
Net decrease in
cash and cash
equivalents (14,911) (9,548)
Cash and cash
equivalents,
beginning of
period 27,884 46,506
---------------------- ----------------------
Cash and cash
equivalents, end
of period $ 12,973 $ 36,958
====================== ======================
Unaudited Reconciliation of Net Loss to EBITDA
(in thousands)
(Unaudited)
Three Months Ended Nine Months Ended
September 30, September 30,
-------------------- ----------------------
2025 2024 2025 2024
--------- --------- --------- -----------
(in thousands)
Net loss $(12,416) $(11,557) $(35,034) $(30,458)
Depreciation
and
amortization
expense 1,072 1,066 3,268 3,258
Interest income (1,733) (2,496) (5,637) (7,838)
Income taxes -- -- -- --
------- ------- ------- -------
EBITDA $(13,077) $(12,987) $(37,403) $(35,038)
Restructuring
expense 3,058 -- 3,058 --
Adjusted EBITDA $(10,019) $(12,987) $(34,345) $(35,038)
======= ======= ======= =======
Unaudited Reconciliation of Gross Margin to Non-GAAP
Adjusted gross margin
(in thousands, except for percentages)
(Unaudited)
Three months ended September 30, 2025 Three months ended September 30, 2024
------------------------------------------ ------------------------------------------
GAAP Adjustments Non-GAAP GAAP Adjustments Non-GAAP
------------ --------------- ----------- ------------ --------------- -----------
Revenue $6,829 $ (423) $6,406 $8,164 $ (24) $8,140
Cost of
Goods
Sold 1,596 (360) 1,236 1,928 (697) 1,231
----- ---- ----- --- ----- --- ----- ---- ----- ---
Gross
Margin 5,233 (63) 5,170 6,236 673 6,909
===== ==== ===== === ===== === ===== ==== ===== ==== ===== ===
Gross
Margin
% 77% 81% 76% 85%
Nine months ended September 30, 2025 Nine months ended September 30, 2024
------------------------------------------ ------------------------------------------
GAAP Adjustments Non-GAAP GAAP Adjustments Non-GAAP
------------ --------------- ----------- ------------ --------------- -----------
Revenue $25,726 $ (2,878) $22,848 $29,934 $ (6,032) $23,902
Cost of
Goods
Sold 4,612 (525) 4,087 4,819 (834) 3,985
------ --- ------- ------ ------ --- ------
Gross
Margin 21,114 (2,353) 18,761 25,115 (5,198) 19,917
====== === ======= ====== ====== === ======= ======
Gross
Margin
% 82% 82% 84% 83%
(1) Adjustments include the exclusion of SPL program related revenue from Revenue, and the exclusion of reserves for excess and obsolete inventory from Cost of Goods Sold.
(END) Dow Jones Newswires
November 12, 2025 16:05 ET (21:05 GMT)
Comments